Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi ...
Silexion Therapeutics Corp Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing ...
Hosted on MSN23d
Silexion reports breakthrough in KRAS cancer therapySilexion Therapeutics, known for its pioneering work in RNAi therapies, has previously achieved promising results in a Phase 2 trial with its first-generation product, LODER™, for non-resectable ...
Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi ...
Silexion Therapeutics Corp. (SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today ...
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models New preclinical findings provide validation for Silexion ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback